Pages that link to "Q27678062"
Jump to navigation
Jump to search
The following pages link to Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans (Q27678062):
Displaying 50 items.
- HIV Genome-Wide Protein Associations: a Review of 30 Years of Research (Q26746070) (← links)
- Harnessing the protective potential of HIV-1 neutralizing antibodies (Q26766153) (← links)
- Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection (Q26775082) (← links)
- The HIV glycan shield as a target for broadly neutralizing antibodies (Q26786540) (← links)
- Recent strategies targeting HIV glycans in vaccine design (Q26823603) (← links)
- Structural insights on the role of antibodies in HIV-1 vaccine and therapy (Q26829461) (← links)
- Antibody responses to envelope glycoproteins in HIV-1 infection (Q26991572) (← links)
- Antibodies in HIV-1 vaccine development and therapy (Q27011574) (← links)
- A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen (Q27302081) (← links)
- Computational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State (Q27303608) (← links)
- SELMA: Selection with Modified Aptamers (Q27343053) (← links)
- Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies (Q27644515) (← links)
- Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer (Q27680496) (← links)
- Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer (Q27680497) (← links)
- The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies (Q27680688) (← links)
- Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign (Q27681806) (← links)
- Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike (Q27683540) (← links)
- Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers (Q27683553) (← links)
- Progress in HIV-1 vaccine development. (Q27693849) (← links)
- Broadly Neutralizing Antibodies for HIV Eradication (Q28073939) (← links)
- Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env (Q28256508) (← links)
- Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope (Q28263655) (← links)
- Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies (Q28263932) (← links)
- Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes (Q28271300) (← links)
- A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies (Q28299280) (← links)
- IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform (Q28543211) (← links)
- Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy (Q28654490) (← links)
- The Patterns of Coevolution in Clade B HIV Envelope's N-Glycosylation Sites (Q30376065) (← links)
- Current views on the potential for development of a HIV vaccine (Q30397595) (← links)
- Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. (Q30490942) (← links)
- Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers (Q30580101) (← links)
- Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals (Q33594304) (← links)
- Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys (Q33597744) (← links)
- Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike (Q33620194) (← links)
- HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies (Q33753573) (← links)
- Which Antibody Functions are Important for an HIV Vaccine? (Q33772637) (← links)
- Synthetic carbohydrate antigens for HIV vaccine design (Q33909079) (← links)
- Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization (Q33946158) (← links)
- Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection (Q34034659) (← links)
- Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody (Q34317887) (← links)
- A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry (Q34509949) (← links)
- Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success (Q34550046) (← links)
- Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo (Q34593860) (← links)
- Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins (Q34721189) (← links)
- Structural evolution of glycan recognition by a family of potent HIV antibodies (Q34782382) (← links)
- Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope (Q34991017) (← links)
- Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions (Q35006601) (← links)
- Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes (Q35076711) (← links)
- A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component (Q35076748) (← links)
- A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene (Q35110976) (← links)